9.8 C
New York
Saturday, November 23, 2024

Top Trade Alert – Aug 24 2022 – Medtronic (MDT)

Medtronic drops despite Q1 beat as currency headwinds weigh on topline

MDT-2.83%

Medtronic (NYSE:MDT) shares traded lower in the morning hours Tuesday even after reporting better-than-expected financials for the first quarter of fiscal 2023 as the medical device maker witnessed a decline in revenue amid currency impact.

Worldwide revenue for Q1 FY23 dropped ~8% YoY to $7.3B on a reported basis. In comparison, the decline stood at only ~4% YoY, excluding a $351M negative impact from foreign currency translation and a $20M contribution from the company’s recent acquisition of Intersect ENT.

The Medical Surgical portfolio led the decline generating $2.0B in revenue for the period with a ~14% YoY drop, while the Cardiovascular portfolio brought $2.7B in revenue with a ~6% YoY contraction.

Meanwhile, the Neuroscience portfolio contracted ~4% YoY, generating $2.1B in revenue, while revenue from the Diabetes segment fell ~5% YoY to $541M as U.S. revenue dropped mid-teens with no new product approvals.

The U.S., the largest contributor to the topline, added $3.8B in revenue with ~8% YoY growth, while non-U.S. developed market revenue fell ~10% YoY to $2.3B. The adj. gross margin reached 66.5% from ~68.8% in Q1 FY22, driving non-GAAP EPS ~17% YoY lower to $1.13.

Chief Executive Geoff Martha noted that the underperformance highlights the supply chain issues and post-COVID recovery in the prior-year period.

“The company’s first quarter organic revenue results reflect the impact of known supply chain shortages, as well as unfavorable comparisons to the prior year given last year’s strong ventilator sales and market procedure recovery following the third COVID-19 wave,” he said.

Reacting to results, Cowen, with an Outperform rating and $117 per share target on MDT, noted that the quarterly report exceeded expectations.

However, the firm added: “as anticipated, macro factors – primarily supply-chain disruption, pressure from inflation and worsening F/X – weighed upon the company’s F1Q results, along with a difficult year-over-year comparison.”

Want to see more?

Reap the benefits of one of our paid membership plans and get access to articles like these PLUS:

  • Insightful daily market reviews
  • Educational guides and posts
  • Access to our Virtual Trading portfolios
  • Unique trading opportunities
  • LIVE trading webinars
  • Intraday market commentary from Phil
  • Our community of traders

Our plans pay for themselves — Don't hesitate!

Join Risk-Free Today!
Already a member? Please sign in.

Stay Connected

156,468FansLike
396,312FollowersFollow
2,320SubscribersSubscribe

Latest Articles